Efficacy Evaluation of SARVONUTRA M as Male Wellness Agent
Phase 2
- Conditions
- Health Condition 1: N538- Other male sexual dysfunction
- Registration Number
- CTRI/2022/05/042708
- Lead Sponsor
- SARVOTHAM CARE LIMITED
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
a) Healthy male individuals.
b) Infertility and low conjugal life for more than 3 months diagnosed with oligospermia (defined by <15 million sperms/ml) as per the WHO standards
c) No past history of renal, hepatic, or any other chronic illness in the past
d) Normal liver, and renal function tests.
e) Patients freely willing and able to provide written informed consent, willing to follow study procedures.
Exclusion Criteria
a) Complete azoospermia in the pre-treatment samples
b) Any congenital anomaly resulting in oligospermia
c) Evidence of male accessory gland infection
d) Any recent medical or surgical illness
e) Hormone/any other treatment for promoting fertility in the last three months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method a) Evaluate the improvements of quality of conjugal life. <br/ ><br>b) Reduction in premature ejaculation <br/ ><br>c) Arousal with lesser foreplay <br/ ><br>d) Improvement in seminal output and motility <br/ ><br>e) If any conceptions during clinical trialTimepoint: 6 - 8 weeks
- Secondary Outcome Measures
Name Time Method a) Changes in mood swing <br/ ><br>b) Better sleep <br/ ><br>c) Improvement in Conjugal Life & WellbeingTimepoint: 6 - 8 weeks